Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.96 Million USD | 92.44% |
| 2022 | 1.02 Million USD | 42.86% |
| 2021 | 715.96 Thousand USD | -16.09% |
| 2020 | 853.22 Thousand USD | 115.2% |
| 2019 | 396.48 Thousand USD | -62.24% |
| 2018 | 1.05 Million USD | 1.98% |
| 2017 | 1.02 Million USD | 0.0% |
| 2009 | 4.96 Million USD | 94.6% |
| 2008 | 2.55 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 1.96 Million USD | 27.62% |
| 2023 Q2 | 1.47 Million USD | 22.17% |
| 2023 Q1 | 1.2 Million USD | 17.78% |
| 2023 Q3 | 1.54 Million USD | 4.8% |
| 2022 Q4 | 1.02 Million USD | 13.13% |
| 2022 Q3 | 904.07 Thousand USD | 6.51% |
| 2022 Q1 | 765.81 Thousand USD | 6.96% |
| 2022 Q2 | 848.79 Thousand USD | 10.84% |
| 2022 FY | 1.02 Million USD | 42.86% |
| 2021 Q4 | 715.96 Thousand USD | -4.03% |
| 2021 FY | 715.96 Thousand USD | -16.09% |
| 2021 Q3 | 746.04 Thousand USD | -9.15% |
| 2021 Q2 | 821.18 Thousand USD | -0.61% |
| 2021 Q1 | 826.19 Thousand USD | -3.17% |
| 2020 Q3 | 783.92 Thousand USD | 10.3% |
| 2020 Q4 | 853.22 Thousand USD | 8.84% |
| 2020 Q2 | 710.71 Thousand USD | 37.17% |
| 2020 Q1 | 518.13 Thousand USD | 30.68% |
| 2020 FY | 853.22 Thousand USD | 115.2% |
| 2019 Q3 | 404.09 Thousand USD | 0.0% |
| 2019 FY | 396.48 Thousand USD | -62.24% |
| 2019 Q4 | 396.48 Thousand USD | -1.88% |
| 2019 Q1 | - USD | -100.0% |
| 2018 Q4 | 1.05 Million USD | 0.0% |
| 2018 FY | 1.05 Million USD | 1.98% |
| 2017 FY | 1.02 Million USD | 0.0% |
| 2010 Q2 | 7.71 Million USD | 71.43% |
| 2010 Q1 | 4.5 Million USD | 90540.4% |
| 2009 Q4 | 4964.74 USD | 0.0% |
| 2009 FY | 4.96 Million USD | 94.6% |
| 2008 FY | 2.55 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 59.205% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | 17.158% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 94.944% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 98.516% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | 29.171% |
| Better Therapeutics, Inc. | 23.84 Million USD | 91.744% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 76.239% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 80.266% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 92.527% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 93.807% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 97.165% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 75.227% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 95.909% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 98.749% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 43.857% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 90.755% |
| Molecular Templates, Inc. | 31.17 Million USD | 93.685% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 84.272% |
| NexImmune, Inc. | 5.08 Million USD | 61.285% |
| Orgenesis Inc. | 35.53 Million USD | 94.461% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 88.079% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -638.826% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | 14.246% |
| Scopus BioPharma Inc. | 7.45 Million USD | 73.595% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.602% |
| Statera Biopharma, Inc. | 22.67 Million USD | 91.32% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 81.965% |
| Trevena, Inc. | 48.26 Million USD | 95.922% |
| Vaxxinity, Inc. | 30.94 Million USD | 93.639% |
| Vaccinex, Inc. | 5.94 Million USD | 66.874% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 94.871% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | 28.724% |